(FinancialPress) – It’s 2018, and once again, the market is in love with medical technology.
Medical devices -the med-tech sector- have been a top performer for the last five years running. Even better than biotech. And 2018 is more of the same.
The med-tech bull is loose again!
Medical devices beat the S&P by 103%, trounce biotechs, too!
You Know Where to Go, Now Zero In
There’s never been a better way to scoop up winners than to find the best companies in the market’s hottest sectors.
That’s why you should turn your attention to Zenosense, Inc. (OTCQB: ZENO), Thermo-Fisher (NYSE: TMO)and Merit Medical Systems (NASDAQ: MMSI).
This is how it goes when med-tech is running high… Look at these gains in less than two years!
- AxoGen is up 512% in 21 months
- Novocure is up 266% in the last 14 months 2017
- Cutera has risen 372% in the past 20 months
And you don’t have to wait for winners, either. The S&P 500 is down 1% to start 1Q 2018, but 26 med-tech stocks are already showing off double-digit gains!1
Take Heart with This…
If you are drawn to potential like this, it doesn’t get any more exciting than
Zenosense, Inc. (OTCQB: ZENO).
Zenosense, through a joint venture ownership in MIDS Medical Ltd, is developing a revolutionary hand-held device to diagnose heart attacks when the chance to save lives is greatest — in the first minutes of the golden hour, as soon as it happens.
This is “point-of-care” technology, the best possible medical approach. It means that whoever responds to a cry for help, paramedics, an emergency clinic, rescue squad, or nurse, can use the Zenosense device to put the patient on the right track within minutes. No need to wait as the clock ticks down for lab tests to come back, no need to worry during a 20–30-minute ambulance ride to wonder what’s really happening.
On June 19, the company released news of breakthrough quantitative product testing results. It was the culmination of seven months work. ZENO “watchers” were primed to buy…and when ZENO shares opened at around 27¢ that day…they started buying.
What happened next was breathtaking; ZENO soared from 27¢ at open to closeat 55¢
Shareholders doubled their money in just one day!
And here’s the kicker…the following day ZENOhit a high of 77¢, which pushed it to a triple off the prior day’s open of 27¢!
It doesn’t happen like this every time, but when it does, you can lock in some impressive gains very quickly!
And just so you know, despite this big two-day gain, we see massive upside potential in Zenosense as it moves ever closer to a final product announcement. Now may be the ideal time to consider a position in ZENO…at a minimum, make sure that ZENO is on your watch list.
Now could be the ideal time to jump in; we believe the company has already achieved key milestones in its R&D.
(Mar, 17): Zenosense, Inc.: MIDS Medical Engages Future Diagnostics for Assay Consulting Services
(Jun, 2017): Zenosense, Inc. has received notice of a patent issuance in the U.S.
(Jul, 2017): Zenosense, Inc. — MIDS Hybrid Strip Detection Testing to Commence
These R&D milestones set the foundation for recent achievements that have firmly validated the company’s technology and moved it well along toward final stages of product development and market release.
(Nov, 2017): Zenosense, Inc.: MIDS Hybrid Strip — Successful Initial Test Results
(Jun, 2018): Zenosense, Inc.: Breakthrough Quantitative MIDS Testing Results
At this point we see these announcements as key signals to investors. Zenosense now appears poised for the kind of explosive growth that we reference above. We therefore recommend you consider ZENO as an immediate buy.
For more conservative investing in medical technology, we also recommend you consider two other healthcare opportunities. The first is an established blue-chip industry leader ThermoFisher (TMO) and the second a reliable growth-oriented mid-cap stock like Merit Medical Systems (MMSI).
ThermoFisher is a leading scientific research company that is incorporating advances in genetics into its diagnostic tools. We see tremendous upside in this arena. Further, ThermoFisher’s leadership across in multiple medical technologies makes it a reliable long-term play — but also consider that this company could be a nice 25%-30% gainer in 2018.
Merit Medical Systems (MMSI) makes disposable medical devices used particularly in cardiology, radiology and endoscopy procedures. Medical disposables have such high margins that some medical device makers earn more on the supplies for their machines than they do on the hardware itself. MMSI also has good potential for 25% to 30% before the year is out.
What to do now…
Do your homework of course. Put these three companies on your Watch List so you will get bulletins each time they make news!
But don’t dither waiting for lightening to strike. You’ll get burned that way. Med-tech stocks can move strongly and suddenly upward on good news.
ZENO’s Market Potential and Position Among the Competition
The global market for cardiac biomarker diagnostic tests is projected to reach $7.2 billion by 2018.
Several other companies are working to overcome the slow turnaround time for results from laboratory analyzers, including Abbott (NYSE:ABT), Roche (SIX:ROG), Alere (NYSE:ALR), and Trinity Biotech (NASD:TRIB). But none of them promises a true high-sensitivity instrument for instantaneous point of care diagnostics like the Zenosense MIDS Cardiac device is developing now.
For example Abbott (now the largest diagnostic company in the world with their acquisition of Alere) acquired i-Stat Corporation for $392 Million in 2003, (an amount which represents over 30X Zeno’s current value!).
i-Stat Corporation specialized in a hand-held blood analyzer for bedside testing and Abbott launched the i-Stat Troponin-I test for cardiac events in 2004. But that doesn’t mean it’s a true competitor to ZENO, because I-Stat cannot match the results of state of the art laboratory analyzers during the early onset of symptoms.
Even with that limitation, the need is so great that i-Stat is now Abbott’s leading handheld device and is used in more than one-third of all U.S. hospitals and emergency rooms.5 Imagine what will happen when a truly accurate ZENO device could be available!
ZENO Is Unique
Being developed to be considerably more accurate that the i-Stat… ZENO’s device is a standout among massive competition.
For instance, Trinity Biotech, which claimed its device was “significantly more accurate than the current established point-of-care tests in the market”6 applied for FDA approval, but it didn’t go well. At the FDA’s request, Trinity abandoned its pursuit, admitting its device could not match the performance of the most recently cleared laboratory analyzer.
That leaves an enormous market opportunity ahead for a device like MIDS Cardiac™, which would not only deliver rapid results but become the first device on the market that also delivers true high sensitivity results equal or exceeding laboratory accuracy.
Headquartered at Sci-Tech Daresbury, a world-class science and innovation campus located in the UK the ZENO development team has over thirty years cumulative experience in magnetic sensors in the medical and bioengineering field.
Faster growth — Sci-Tech Daresbury companies have seen sales grow at 30%/year over the past 5 years
More investment — Daresburg companies raised over 80m to date.
500 new products and services in the last 4 years
Incorporating the patented MIDS technology, MIDS Cardiac™ uses highly sensitive, custom built “Hall Effect” magnetic sensors embedded within a disposable microfluidic test strip as a “Lab-On-Chip” device.
This can detect extremely low levels (nano-Tesla) of magnetic field disturbance caused by the test particles used in immunoassay tests. That is what makes MIDS Cardiac™ different from anything else on the market. Detection at these levels is unheard of and should allow accuracy and speed of results, which will significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected AMI.
That’s why the ZENO team scientists give this small company such an edge:
Chief Scientific Officer
MIDS Medical Ltd.
20 years expertise in Hall Effect technology and magnetic field measurement
Nanoparticle and sensor design for bio-medical and bio-sensing medical Point of Care devices.
We’ve already told you the MIDS device is striving to achieve gold-standard results right at the point of care. That alone will make it unique and open a huge slice of the cardiac healthcare market to ZENO.
But there’s a lot more behind this product’s likely future success that makes it a game changer for emergency medicine:
A game-changing Point of Care sensitivity and accuracy improvement, equal or superior to high sensitivity cardiac biomarker assays performed on central laboratory analyzers
Patient friendly, tiny finger prick sample rather than treated venous blood draw
An industry leading tiny 5 microliter blood sample, 3 to 400 times smaller (1 assay) than existing Point of Care devices for cardiac marker tests
Test times 3 to 7 times faster (1 assay) than existing Point of Care devices
Capable of 3 multiplexed assays (3 cardiac biomarkers in a single test strip)
Automated operation by minimally trained personnel even in an ambulatory setting
Considerably more cost effective for healthcare providers than existing test devices
Conclusion — There Are Three Great Stocks Here
We like Thermo Fisher, especially for a conservative portfolio. And we believe MMSI’s growth rate should help it to do very well this year, though we have less faith in the longer term.
But we think investors looking for a home run should be excited about ZENO’s prospects.
We believe that a technology that can match or exceed state-of-the-art laboratory accuracy and deliver results rapidly in a cost-effective device the size of an average smart phone will be in universal demand. That’s what ZENO is promising, and could deliver.
Not only would ZENO’s device, the MIDS Cardiac™ meet a critical medical need for the first time, it would undoubtedly attract a very substantial valuation.
Here, i-Stat serves as a useful aid for diagnosis. Its device falls well short of the state of the art laboratory analyzers, and yet, it can command a price tag of nearly $400 million. That suggests that an enormous valuation for MIDS Cardiac™ is achievable.
If the MIDS Cardiac device succeeds as we expect, the long term could be even more dynamic. By adapting the MIDS technology to numerous other immunoassay tests, ZENO could access a market that is projected to be worth $23.7 billion per year worldwide by 2019.
With unheard accuracy levels and industry leading features on every level MIDS Cardiac™ is a true blockbuster in the making and ZENO has potential to be the high growth stock of 2018 and way beyond.
For news releases from Thermo Fisher, go to:
For news releases from Merit, go to:
For news releases from ZenoSense, go to:
This financial news and information portal (newbiotechstock.com), and/or our newsletters contain commercial advertisements, and are for general entertainment purposes only. Along with the aggregation of timely financial news, we are engaged in the business of analyzing, marketing and advertising companies for monetary compensation. Unless otherwise stated below, the paying Third Party for our services may own shares and may liquidate them during any and all advertising periods. This disclaimer is to be read and fully understood before using newbiotechstock.com, or joining one of our newsletter/email lists. We also encourage you to read the SEC INVESTOR ALERT before reading content found on newbiotechstock.com and/or our newsletters. You are reading content found on our financial news and informational portal because you have clicked on an advertisement found on one of many marketing channels we advertise on. newbiotechstock.com is for entertainment purposes only. We are NOT a source of unbiased information. Never invest in any stock featured on our site or newsletters unless you can afford to lose your entire investment. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled on the website/newsletter and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead, newbiotechstock.com strongly urges you to supplement the information obtained from this website/newsletter with a complete and independent investigation of the companies discussed and a consideration of all pertinent risks. Investing in securities, including the securities of the companies profiled or discussed on this website/newsletter, is highly speculative and carries a high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies discussed. The information found on newbiotechstock.com, and/or our newsletters are based on sources, which we believe to be reliable, but are not guaranteed by us as being accurate and do not purport to be a complete statement or summary of the available data. newbiotechstock.com encourages readers and investors to supplement the information found on our site or in our newsletters with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources. newbiotechstock.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the featured companies None of the owners of newbiotechstock.com, or any of its directors, officers, employees, contractors, or affiliates is a licensed broker-dealer, account representative, market maker, investment banker, investment advisor, analyst or underwriter in any jurisdiction whatsoever. newbiotechstock.com does not offer such advice or analysis, and newbiotechstock.com further urges you to consult your own independent tax, business, financial and investment advisors before purchasing or selling any securities of the companies discussed on this website/newsletter. Compensation: newbiotechstock.com may be compensated for up to one hundred thousand USD via bank wire by a third party for continuous analyzing, marketing and advertising services. newbiotechstock.com does not own any shares of any featured company. The paying third party may own shares and may sell all, any or none of any shares held in any featured company during advertisement periods, which may negatively affect the featured company’s stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the featured company. newbiotechstock.com and its employees, contractors, officers, directors, or affiliates may purchase shares on the open market of any mentioned featured company during advertisement periods and following the dissemination of any newsletters. This is an inherent conflict of interest. The services provided by this website/newsletter and its contents are provided “as is” and newbiotechstock.com makes no representations or warranties of any kind with respect to this website/newsletter, its contents or its services. This website/newsletter has been prepared solely for the purpose of providing information about newbiotechstock.com and the services it offers. This website/newsletter has been compiled in good faith by newbiotechstock.com. newbiotechstock.com assumes no liability or responsibility for any errors or omissions in the content of this website/newsletter, any failures, delays, or interruptions in its services or any content contained on this website/newsletter, any losses or damages arising from the use of the content provided on this website/newsletter, or any conduct by users of newbiotechstock.com’s services. newbiotechstock.com reserves the right to add, modify or delete any information at this website/newsletter at any time. This website/newsletter may contain “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In accordance with the safe harbor provisions of this Act, statements contained herein that look forward in time that includes everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results. There can be no assurance that such statements will prove to be accurate and there are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made in this report. Further specific financial information, filings, and disclosures as well as general investor information about the profiled companies, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org.newbiotechstock.com undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise. In addition to information about the company discussed, from time to time, this website/newsletter may contain the symbols of companies and/or news feeds or links to websites about companies that are not being discussed by us but are merely illustrative of certain activity in the stock market that we are highlighting (so-called hyperlinks to third party websites or access to third party content). Readers are advised that all links and access to these sites and content solely for informational purposes. newbiotechstock.com, its owners, directors, officers, employees, affiliates, and contractors are not responsible for errors and omissions nor does newbiotechstock.com control, endorse, or guarantee any content found in such sites or content. Any opinions expressed are subject to change without notice. It is also possible that the companies discussed on those sites may not have approved certain or any statements within the report. By accessing or viewing this website/newsletter, you agree that newbiotechstock.com, its owners, directors, officers, employees, affiliates and contractors are not responsible for any content, associated links, resources, or services associated with a third-party website. newbiotechstock.com uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. In no event shall newbiotechstock.com, its owners, directors, officers, employees, affiliates and contractors be liable (jointly or severally) for any special, incidental, indirect or consequential damages of any kind, or any damages whatsoever resulting from loss of use, data or profits, whether or not advised of the possibility of damage, and on any theory of liability, arising out of or in connection with this website/newsletter. You agree to hold newbiotechstock.com, its owners, directors, officers, employees, affiliates and contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur arising out of the use of the information contained on this website/newsletter (including any loss or damage of any sort associated with your use of third party content). You agree that use of this website/newsletter is at your sole risk. newbiotechstock.com disclaims all warranties of any kind, express or implied. If any applicable authority holds any portion of this section to be unenforceable, then liability will be limited to the fullest possible extent permitted by applicable law. newbiotechstock.com encourages readers to invest carefully, and read investor and issuer information available at the websites of the SEC. The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov . In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/investors/index.htm.Questions regarding any information contained on this website/newsletter may be sent to firstname.lastname@example.org. To review newbiotechstock.com’s website and its disclaimer, please visit www.newbiotechstock.com
A New Spin on CBD: Quanta Upping the Game with Bioenergy
Cannabidiol, or CBD for short, a component of cannabis, is all the rage today, underscored by President Trump last week signing the U.S. Farm Bill 2018 into law. After decades of being held to the same standard as cannabis that contains THC, hemp is finally removed from the Controlled Substance Act, effectively making hemp-based CBD legal at the federal level.
Cannabis and hemp are similar with one major differentiator: THC (tetrahydrocannabinol), the cannabinoid in cannabis responsible for the psychoactive high, or “stoned” feeling from ingesting marijuana. Hemp contains little to no THC, but does contain CBD, a non-psychotropic cannabinoid widely acclaimed for a litany of medical uses, including applications for hard-to-treat diseases like epilepsy and PTSD, as well as more casual uses, such as skincare.
With the passage of the Farm Bill, hemp-based CBD – which still falls under the regulatory scrutiny of the U.S. Food and Drug Administration – is legal for a bevy of development activity.
The scientists at Quanta (OTC: QNTA) are putting a new spin on cannabinoids, specifically CBD, amplifying the benefits by using the combination of quantum physics and biochemistry to increase bioenergy within the cell. As explained in a corporate video, this produces a better chemical reaction in the body.
The science is based in part on principles of quantum physics proving that everything in the universe is energy and has its own vibration, or vibrational frequency more specifically, including cannabinoid receptors. Cannabis, by virtue of its properties as a plant, is losing vibrational power every day. Quanta uses a patented technology to retrain the vibrations within cannabinoids, which raises their bioenergy, until they have identical frequencies to the body’s cannabinoid receptors.
When these matching frequencies combine, the highest possible response is the result and the CBD is absorbed into the body more efficiently with little to no side effect. This takes each element in Quanta’s formula to peaks levels of performance, meaning the user enjoys a better experience in reduction of things like pain, inflammation, stiffness and anxiety that CBD is heralded for delivering.
Quanta’s lead product is CBD Muscle Rub, a combination of 13 natural elements including turmeric, arnica and polarized CBD, administered topically for the relief of muscle and joint pain and stiffness.
While the initial focus is on hemp-based CBD, the technology is available for licensing or product development that can be applied to all types of plant matter to enhance energy in naturally occurring molecules utilizing the same properties of the Law of Vibration and the fact that humans are bio-electric beings. In addition to the effect on muscles and joints, the complete Quanta process, which involves identifying natural elements by their frequency and using magnetic and electric frequencies to illicit changes at the sub-atomic level to make the
targeted molecules move faster to create a bond in receptors for an energized and frictionless experience, have been shown to significantly reduce anxiety, paranoia, cognitive haze and drowsiness.
One Million Users and Counting: MassRoots Connecting Consumers and Cannabis Dispensaries
The passage of the 2018 U.S. Farm Bill, officially called the Agricultural Improvement Act of 2018, is expected to bolster the already rapidly emerging hemp industry as it finally legalized industrial hemp and cannabidiol (CBD) that comes from hemp. The signing of the bill has been widely cheered by cannabis industry advocates that argue the broad reaching medicinal benefits of CBD, ranging from anti-aging properties to controlling seizures.
Hemp is defined as cannabis (Cannabis sativa L.) and derivatives of cannabis with extremely low (less than 0.3 percent on a dry weight basis) concentrations of the psychoactive compound delta-9-tetrahydrocannabinol (THC). In layman’s terms, it’s the type of cannabis that doesn’t have the “high” due to THC that is commonly associated with marijuana. For decades, hemp, regardless of its non-intoxicating nature, has been illegal as a Schedule I drug under the Controlled Substance Act and only allowed to be grown under specific conditions for research purposes as allowed by state law. The Farm Bill changed that.
Little credence has been given to the therapeutic effects of CBD by many pundits due to the lack of clinical research that has been limited because of federal prohibition. However, with medical marijuana now legal in 33 U.S. states – and recreational marijuana legal in 10 states and the District of Columbia – there is no shortfall of advocates touting its benefits.
Further, the U.S. Food and Drug Administration this year gave marketing approval to GW Pharmaceuticals’ Epidiolex, a CBD therapy for treating rare types of epilepsy, making it the first cannabis-based drug ever given the green light, which throws a dart into the notion that CBD has no medical use.
MassRoots (OTCQB: MSRT) is a leading technology platform for the regulated cannabis industry centered on information and connectivity that allows businesses to reach consumers and consumers to make educated purchases based on consumer reviews of thousands of cannabis products. The platform has a wide influence with more than one million registered users.
With the trend towards CBD gaining momentum, MassRoots is preparing to launch a new review and e-commerce platform focused on CBD products. The existing platform has already generated “tens of thousands” of reviews on CBD products, information the company believes will be able to expand its audience by being presented separately from products containing THC. Given its large user base and shift in hemp laws effective January 1, 2019, the opportunity for an online platform offering CBD products is not going overlooked by MassRoots.
On the business side, the company offers its MassRoots for Business portal. The fully-integrated platform was recently loaded with new features and analytics for its dispensary customers expected to drive additional traffic and provide greater insight into consumer behavior. Business clients pay a monthly fee for listing on the MassRoots platform, as well as fees for the company’s new WeedPass Rewards program that enables consumers to earn
rewards (for example, tickets to movies and sporting events) by shopping at dispensaries participating in WeedPass.
Upon the acquisition of the WeedPass.com domain this month, MassRoots initiated an online marketing campaign, comprised of leading cannabis social media influencers on Instagram, SnapChat, Twitter and MassRoots.
Launched only a few months ago, more than 100 dispensaries are already participating in the WeedPass program in the Los Angeles and Denver markets, driving over $120,000 in sales to those dispensaries. There is still plenty of headroom for expansion as measured by New Frontier Financial’s estimate that there are more than 2,500 regulated dispensaries in the U.S.
To that end, MassRoots says it intends to widen the availability of WeedPass outside of California and Colorado into every state with a regulated cannabis market. With Michigan legalizing recreational marijuana and Utah and Missouri making medical marijuana legal by ballot measure last month, the company’s addressable market just got a little bigger.
Selling Convenience in a Bottle: Driven Leading Public Cannabis Delivery Companies
The world today has become increasingly “on demand.” Whether it is a movie, laundry soap or food, people want what they want, and they want it delivered to their doorstep right now. A $6 billion valuation for GrubHub and Amazon growing into one of the world’s biggest companies speak clearly to macro-trends favoring the on-demand dynamic.
With cannabis legalization sweeping the nation, why would we expect anything different for this consumer product? The answer is: “We shouldn’t.” To that point, as regulators have been hammering out guidelines to ensure safety and standardization, select companies have been gaining traction with their cannabis delivery businesses as the market starts to grow.
In the U.S., Driven (OTC: RBOS), which likens itself to “GrubHub for cannabis,” is the only publicly traded cannabis delivery service. With plans to expand into Nevada, Arizona and Michigan in 2019, the company currently operates exclusively throughout its home state of California, a market where medical marijuana has been legal for about 20 years and recreational cannabis was legalized at the start of 2018. California is hands down the market stalwart, with Arcview Market Research and its partner BDS Analytics forecasting the legal cannabis market to reach $5.1 billion in the next year.
More broadly, the industry research group sees the U.S. market climbing three-fold to $23.3 billion in the five years to 2022. With the latest ballots in November, recreational marijuana is legal in 10 states and the District of Columbia, while medicinal cannabis is allowed in 33 states.
Against that backdrop, Driven CEO Chris Boudreau believes that cannabis delivery represents a $600 million opportunity for the company, according to a presentation at the annual LD Micro Conference earlier this month. A commercial banking executive by trade, Boudreau found success in his foray into cannabis a decade ago, helping to build California’s Kindest into one of the largest retail delivery cannabis companies and Sunstone Distribution into the first statewide wholesale cannabis distribution company.
Driven differentiates itself from rival Eaze through its last-mile delivery model. More specifically, Driven operates through a “Bag and Carry” model, where it can work with any and all dispensaries to deliver specific product ordered by the dispensary’s customers. Eaze utilizes a “Mobile Dispensary” model, where it works with only one dispensary in a local market, shuttling product around in a manner similar to an ice cream truck (although obviously not advertising its vehicles as such).
Driven uses a complete tracking system to ensure regulatory compliance and security. A turnkey infrastructure allows Driven to get a dispensary up and running with a delivery service in under two weeks. Now more than just a delivery service, the tech company earlier this year folded-in its own marketing and marketplace, for which it charges the dispensary a premium for initiating sales.
This has catalyzed sales since being rolled out. In May, for example, 169 deliveries were initiated by the dispensary and 22 were pushed through by Driven. During August, those figures rose to 469 and 134, respectively.
The efforts have resulted in approximately 4,500 deliveries in the last six months for Delivered.
Medicine Man Technologies: Showing Cannabis Companies How It’s Done
Backstopped by Science, CBD Unlimited Aiming for 30,000 Distribution Points
With Mayo Clinic in its Corner, BioSig Aligns for Commercialization of PURE EP System Improving Catheter Ablations for AFib and VT Patients
ZTE replaces 14 board members in compliance to US deal
US consumers are now noticing inflation
Starbucks to start accepting bitcoin
Breaking7 months ago
ZTE replaces 14 board members in compliance to US deal
Uncategorized5 months ago
US consumers are now noticing inflation
Breaking5 months ago
Starbucks to start accepting bitcoin
Breaking5 months ago
Social Life Network Steadily Building Portfolio, Strong Team
Breaking5 months ago
PepsiCo CEO Nooyi set to step down
Breaking5 months ago
Is the crypto boom over? Nvidia forecasts drop in sales
Breaking5 months ago
Amazon CEO wants employees to ‘wake up every morning terrified’
Breaking5 months ago
Trump mulls major changes to earnings report requirements